FDA Withdraws Kratom and Psychedelics Study Amid Criticism
The FDA has unexpectedly withdrawn its request to study kratom and psychedelics, facing criticism for its methodology and potential bias against harm reduction approaches.
Kratom, a tropical tree with opiate-like properties, is used by millions of Americans for pain relief, anxiety, and other conditions. The FDA's proposed study, which aimed to assess the risks and benefits of kratom and psychedelics, drew criticism for its attempt to link the two distinct substances and for its perceived bias against kratom.
Advocates for both kratom and psychedelics argue that the FDA's actions reflect a broader resistance to harm reduction strategies. They see the withdrawal of the study request as a victory against unwarranted regulatory overreach.
The future of kratom and psychedelic research in the U.S. remains uncertain, with the FDA's skepticism towards these substances despite growing public interest and scientific evidence of their potential benefits.